Andere talen Allergy Therapeutics plc

Aandelen

AGY

GB00B02LCQ05

Beurs gesloten - London S.E. Andere beurzen 17:35:18 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,85 ^GBX	0,00%		+7,55%	+14,00%

03/04	Allergy Therapeutics kondigt het ontslag aan van Mary Tavener als niet-uitvoerend bestuurder	CI
27/03	Allergy Therapeutics krijgt toestemming om 15 miljoen pond op te nemen van gewijzigde kredietfaciliteit	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Allergy Therapeutics Announces Resignation of Mary Tavener as Non-Executive Director	03/04
EARNINGS AND TRADING: Solid State ups outlook; Quartix trading in line	27/03
Allergy Therapeutics Gets OK to Draw Down GBP15 Million From Amended Loan Facility	27/03
AIM WINNERS & LOSERS: Norman Broadbent profit swing on rising revenue	27/03
Earnings Flash (AGY.L) ALLERGY THERAPEUTICS Reports Fiscal H1 Revenue GBP33.6M	27/03
Earnings Flash (AGY.L) ALLERGY THERAPEUTICS Posts Fiscal H1 Loss GBX-0.58	27/03
Allergy Therapeutics plc Provides Sales Guidance for the Second Half and Full Year Ending on 30 June 2024	27/03
Allergy Therapeutics plc Reports Earnings Results for the Half Year Ended December 31, 2023	27/03
Allergy Therapeutics starts dosing patients in peanut allergy trial	12/03
Allergy Therapeutics Announces Commencement of Subcutaneous Dosing of Peanut Allergic Patients in the Phase I/IIa PROTECT Trial Evaluating its Novel Virus-Like Particle Based Peanut Allergy Vaccine Candidate	12/03
Allergy Therapeutics plc Announces Appointment of Shaun Furlong to Board of Directors	11/03
Allergy Therapeutics forecasts revenue drop but trials going well	14/02
Alliance Pharma appoints chair; FireAngel sales down	05/02
Scancell's Chief Development Officer to Step Down	05/02
Allergy Therapeutics plc - Publication of Annual Report and Accounts 2023	31/01
Allergy Therapeutics resumes trading on AIM; annual revenue plunges	30/01
Allergy Therapeutics amends facility, plans warrant issue	27/12
Allergy Therapeutics Agrees Amendment to Loan Facility	27/12
EARNINGS AND TRADING: Redx full year revenue tumbles; loss widens	15/12
Allergy Therapeutics' Allergic Rhinoconjunctivitis Treatment Returns Positive Data in Late-stage Trial	13/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Allergy Therapeutics plc

Aandelen

AGY

GB00B02LCQ05

Andere talen

Filters